Discovery of C₂₀-Diterpenoid Alkaloid Kobusine Derivatives Exhibiting Sub-G1 Inducing Activity

Abstract

Although many diterpenoid alkaloids have been evaluated recently for antiproliferative activity against human cancer cell lines, little data have been offered relating to the antiproliferative effects of hetisine-type C₂₀-diterpenoid alkaloids, such as kobusine (1), likewise as their derivatives. A total of 43 novel diterpenoid alkaloid derivatives (2–10, 2b, 3a, 3b, 6a–16a, 7b, 9b, 10b, 13, 15–26, 15b, 18a, 23a, 27a) were prepared by C-11 and -15 esterification of 1. Antiproliferative effects of the natural parent compound (1) and all synthesized kobusine derivatives against human cancer cell lines, including a triple-negative breast cancer (TNBC) cell line as well as a P-glycoprotein overexpressing multidrug-resistant subline, were assessed. The structure-based design strategy resulted in the lead derivative 11,15-dibenzoylkobusine (3; average IC₅₀ 7.3 μM). Several newly synthesized kobusine derivatives (particularly, 5–8, 10, 13, 15–26) exhibited substantial suppressive effects against all tested human cancer cell lines. In contrast, kobusine (1), 11,15-O-diacetylkobusine (2), 11-acylkobusine derivatives (3a, 6a, 9a, 11a, 12a, 15a, 27a), and 15-acylkobusine derivatives (2b, 3b, 7b, 9b, 10b, 15b) showed no effect. The most active kobusine derivatives primarily had two specific substitution patterns, C-11,15 and C-11. Notably, 11,15-diacylkobusine derivatives (3, 6–10, 13, 15, 16, 18, 23) were more potent compared with 11- and 15-acylkobusine derivatives (3a, 3b, 6a–10a, 7b, 9b, 10b, 13a, 15a, 15b, 16a, 18a, 23a). Derivatives 13 and 25 induced MDA-MB-231 cells to the sub-G1 phase within 12 h. 11,15-Diacylation of kobusine (1) appears to be crucial for inducing antiproliferative activity in this alkaloid class and could introduce a new avenue to overcome TNBC using natural product derivatives.

Introduction

Chemotherapy refers primarily to the usage of cytotoxic small molecules for cancer treatment, and natural products are major sources of currently available chemotherapeutics. Based on a review of New Chemical Entities (NCE) from 1981 to 2019, nearly 75% of antitumor agents are not purely synthetic compounds, with 47% either being natural products including their derivatives or mimicking natural products.¹ A great variety of chemically and biologically active anticancer agents are used in cancer chemotherapy, and classical plant alkaloids such as vincristine and paclitaxel are still commonly used in clinical practice.²⁻¹⁰ While studies on the phytochemistry and synthetic and medicinal chemistry of diterpenoid alkaloids have led to the discovery of remarkable pharmacological activities and structural complexity, little facts at the antiproliferative properties have been reported.

A large number of diterpenoid alkaloids isolated from various species of Aconitum and Delphinium (Ranunculaceae) have been identified as the main bioactive constituents related to both toxicity and medical uses.¹¹ These diterpenoid alkaloids are categorized in line with their chemical structure as C₁₉-diterpenoid alkaloids, which have a lycoctonine or an aconitine skeleton, and C₂₀-diterpenoid alkaloids, which have a veatchine or an atisine skeleton.¹² The former group contains aconitine, mesaconitine, hypaconitine, and jesaconitine, which are extraordinarily toxic, while compounds in the latter group, together with lucidusculine, kobusine (1), pseudokobusine, and atisine, are much less toxic.¹¹ The pharmacological properties of the C₁₉-diterpenoid alkaloids have been studied expansively and reviewed.¹³ However, the pharmacological characteristics of the C₂₀-diterpenoid alkaloids and their derivatives have been less investigated.

Our earlier study confirmed the effects of several semi-synthetic and natural diterpenoid alkaloids on growth of the A172 human malignant glioma cell line.¹⁴ Effects of various types of novel diterpenoid alkaloid derivatives on antiproliferation and radiosensitization were also studied.¹⁵ Two novel hetisine-type C₂₀-diterpenoid derivatives exhibited noteworthy suppressive effects against the Raji non-Hodgkin’s lymphoma cell line.¹⁶ Moreover, the effects of several novel hetisine-type C₂₀-diterpenoid alkaloid derivatives on the growth of the A549 human lung cancer cells were examined, and subsequent structure–activity relationships (SAR) for the antiproliferative activities against A549 cells were reported.¹⁷ In previous pharmacological studies, several diterpenoid alkaloids and their derivatives displayed antiproliferative activity against several human cancer cell lines, including A549 (lung carcinoma), DU145 (prostate carcinoma), KB (cervical carcinoma HeLa derivative), and its MDR subline KB-VIN (P-gp overexpressing vincristine-resistant KB subline).^18,19 As recently reported, we evaluated lycoctonine-type C₁₉-diterpenoid alkaloids, delcosine, 14-acetyldelcosine, and 14-acetylbrowniine, and synthesized derivatives for antiproliferative effects against five human cancer cell line panels {A549, MDA-MB-231 [triple-negative breast cancer (TNBC), hormone receptor-negative and HER2-negative], MCF-7 (estrogen receptor-positive, HER2-negative breast cancer), KB, and KB-VIN}.²⁰ Among such diterpenoid alkaloids, lycoctonine-type C₁₉-diterpenoid and C₂₀-diterpenoid alkaloid derivatives exhibited significant antiproliferative activity and, thus, provided promising novel leads for further development as antineoplastic agents. Less data are available regarding the antiproliferative properties of natural hetisine-type C₂₀-diterpenoid alkaloids as well as their derivatives. However, 11,15-dibenzoylkobusine (3) exhibited significant potency against A549, KB, and KB-VIN cell lines (average IC₅₀ 7.3 μM), although the natural parent alkaloid kobusine (1), a hetisine-type C₂₀-diterpenoid alkaloid, and 11,15-diacetylkobusine (2) were inactive (IC₅₀ > 20 μM) against the same three cell lines.¹⁹ Therefore, in this current study, prior and newly synthesized kobusine derivatives were evaluated for antiproliferative activity against five human cancer cell line panels (A549, MDA-MB-231, MCF-7, KB, and KB-VIN).

Results and Discussion

Kobusine (1), a hetisine-type C₂₀-diterpenoid alkaloid, was purified from Aconitum yesoense var. macroyesoense (NAKAI) TAMURA (Ranunculaceae) by a previously described procedure.^21,22 Kobusine (1) was reacted with various acyl chlorides in pyridine (Figure 1) to give C-11-, C-15-, or C-11,15-substituted acyl derivatives (4–10, 13, 15–26, 3a, 3b, 6a–16a, 7b, 9b, 10b, 15b, 18a, 23a, 27a) (Figure 2). The synthesized derivatives (4, 5, 7–9, 7a–9a, 7b, 9b, 13, 13a, 16–25, 16a, 18a, 23a) were evaluated for antiproliferative activity against our five human cancer cell line panels. Paclitaxel was used as an experimental control (data shown in Table 1). In this study, previously synthesized 18 derivatives (2, 2b, 3, 3a, 3b, 6, 6a, 10, 10a–12a, 10b, 14a, 15, 15a, 15b, 26, 27a) were evaluated for antiproliferative activity against human cancer cell lines [A549, DU145, KB, and KB-VIN].¹⁹

Figure 1.

Synthesis of kobusine derivatives.

Figure 2.

Chemical structures of derivatives 1–27a.

Table 1. Antiproliferative Activity of Kobusine (1) and Derivatives 2–27a.

	cell line/IC50 (μM)a
alkaloid	A549	MDA-MB-231	MCF-7	KB	KB-VIN
1c	>20			>20	>20
2c	>20			>20	>20
2bc	>20			>20	>20
3c	8.4			6.0	7.5
3ac	>20			>20	>20
3bc	>20			>20	>20
4	17.0	19.0	13.4	13.0	16.1
5	4.5	4.5	4.7	4.7	4.8
6c	6.7			5.3	5.2
6ac	>20			>20	>20
7	4.4	4.7	4.2	4.2	4.6
7a	19.5	21.2	26.9	19.9	28.9
7b	>40	>40	>40	>40	>40
8	4.5	4.6	5.2	4.6	5.0
8a	7.8	15.9	18.0	8.9	11.2
9	19.5	19.9	18.3	17.4	19.1
9a	>40	>40	>40	>40	>40
9b	>40	>40	>40	>40	>40
10c	6.9			5.3	5.5
10ac	19.5			13.9	17.9
10bc	>20			>20	>20
11ac	>20			>20	>20
12ac	>20			>20	>20
13	4.8	4.5	4.7	4.6	4.8
13a	18.1	19.3	19.6	18.1	20.1
14ac	14.1			11.7	10.9
15c	8.1			5.2	7.1
15ac	>20			>20	>20
15bc	>20			>20	>20
16	4.6	4.8	4.9	4.5	4.7
16a	30.0	32.1	29.5	27.1	33.2
17	4.5	4.6	4.6	4.4	4.6
18	4.5	5.0	4.6	4.7	4.6
18a	27.9	26.8	23.8	28.7	31.1
19	4.5	4.4	4.7	4.5	5.2
20	5.3	6.4	6.3	5.1	5.6
21	4.4	4.7	4.7	4.7	4.6
22	4.5	2.8	5.3	5.1	5.7
23	4.4	4.5	4.5	4.6	4.6
23a	20.4	21.0	18.6	21.5	21.0
24	5.2	4.4	5.3	4.8	5.7
25	4.4	4.2	4.5	4.5	4.6
26c	5.5			4.1	3.1
27ac	>20			>20	>20
paclitaxelb	0.0052	0.0067	0.0073	0.0050	1.3

^aAntiproliferative activity as IC₅₀ values for each cell line, the concentration of the derivative that caused 50% reduction in growth relative to untreated cells as determined by the SRB assay.

^bPaclitaxel was used as an experimental control.

^cSee ref (19).

With three exceptions [11-acyl derivatives 11a, 12a, and 27a, containing a 2-trifluoromethylbenzoyl, 3-trifluoromethylbenzoyl, or nicotinoyl group, respectively, were inactive (IC₅₀ > 20 μM)], acylation of the C-11 and/or C-15 hydroxy group of kobusine (1) led to various degrees of antiproliferative activity. Among the derivatives esterified at both C-11 and -15, derivatives 5 [11,15-di-(3-methoxybenzoyl)kobusine], 6 [11,15-dianisoylkobusine], 7 [11,15-di-(3,4,5-trimethoxybenzoyl)kobusine], 8 [11,15-di-(4-ethoxybenzoyl)kobusine], 10 [11,15-di-p-nitrobenzoylkobusine], 13 [11,15-di-(4-trifluoromethylbenzoyl)kobusine], 15 [11,15-di-(4-fluorobenzoyl)kobusine], 16 [11,15-di-(4-fluoro-3-methylbenzoyl)kobusine], 17 [11,15-di-(3-chloro-4-fluorobenzoyl)kobusine], 18 [11,15-di-(2,4,5-trifluoro-3-methoxybenzoyl)kobusine], 19 [11,15-di-(2,3,4,5,6-pentafluorobenzoyl)kobusine], 20 [11,15-di-(2-chlorobenzoyl)kobusine], 21 [11,15-di-(3-chlorobenzoyl)kobusine], 22 [11,15-di-(4-chlorobenzoyl)kobusine], 23 [11,15-di-(3,5-dichlorobenzoyl)kobusine], 24 [11,15-di-(4-chloro-3-nitrobenzoyl)kobusine], 25 [11,15-di-(4-dichloromethylbenzoyl)kobusine], and 26 [11,15-di-(3-trifluoromethylcinnamoyl)kobusine] exhibited significant potency against three to five human cancer cell lines (average IC₅₀ 4.2–6.8). Derivatives 4 [11,15-di-(2-methoxybenzoyl)kobusine] and 9 [11,15-di-(3-nitrobenzoyl)kobusine] showed moderate potency against all five human cancer cell lines (average IC₅₀ 15.7 and 18.8 μM, respectively). Although derivative 4 displayed good antiproliferative activity against MCF-7 and KB cells (IC₅₀ 13.4 and 13.0 μM, respectively), it was much less active against A549, MDA-MB-231, and KB-VIN cells.

Among the C-11 esterified derivatives, derivatives 8a [11-(4-ethoxybenzoyl)kobusine], 10a [11-p-nitrobenzoylkobusine], 13a [11-(4-trifluoromethylbenzoyl)kobusine], and 14a [11-(4-trifluoromethoxybenzoyl)kobusine] exhibited moderate potency against three to five tested cell lines (average IC₅₀ 12.4, 17.1, 19.0, and 12.2 μM, respectively). Derivative 8a showed significant antiproliferative activity against A549, KB, and KB-VIN cells (IC₅₀ 7.8, 8.9, and 11.2 μM, respectively) but was less active against MDA-MB-231 and MCF-7 (IC₅₀ 15.9 and 18.0 μM, respectively). Derivatives 7a [11-(3,4,5-trimethoxybenzoyl)kobusine], 16a [11-(4-fluoro-3-methylbenzoyl)kobusine], and 18a [11-(2,4,5-trifluoro-3-methoxybenzoyl)kobusine] exhibited only weak potency against all five human cancer cell lines (average IC₅₀ 23.3, 30.4, and 27.7 μM, respectively). Derivatives 3a, 6a, 9a, 11a, 12a, 15a, and 27a were inactive against all tested human cancer cell lines. All five C-15 esterified derivatives, 3b, 7b, 9b, 10b, and 15b, were also inactive against all tested human cancer cell lines.

Particularly, C-11,15 diacylated kobusine derivatives (3, 6–10, 13–16, 18) showed significantly better potency compared with the corresponding C-11 or -15 monoacylated kobusine derivatives (3a, 3b, 6a–10a, 7b, 9b, 10b, 13a–16a, 18a). Thus, C-11,15 diesterification was crucial for enhanced antiproliferative activity of kobusine (1) derivatives.

Prominent observations from the data in Table 1 were the reliable identities of the most active derivatives. Kobusine derivatives 5–8, 10, 13, and 16–26 displayed the highest potency against all tested cancer cell lines with IC₅₀ values ranging from 2.8 to 6.9 μM. A similar range of potency was found with derivatives 3 and 15 against KB cells (6.0 and 5.2 μM, respectively). The potencies of 3, 8a, and 15 (IC₅₀ 5.2–11.2 μM) generally graded somewhat below those of the most potent derivatives, except against MDA-MB-231 and MCF-7 cell lines, where they were even less active. Derivative 14a showed moderate activity against KB and KB-VIN (11.7 and 10.9 μM, respectively).

The identity of the substituent(s) on the acyl group affected the cytotoxic potency. Notably, among the C-11,15 disubstituent derivatives, derivatives 5–8, 10, 13, and 16–26 with variously substituted benzoyl or cinnamoyl esters showed significant potency against all tested human cancer cell lines. Among derivatives with small alkoxy groups on the benzoate esters, 5 (3-methoxy), 6 (4-methoxy), 7 (3,4,5-trimethoxy), and 8 (4-ethoxy) were more potent than 4 (2-methoxy). Derivative 5 (3-methoxybenzoyl) was more potent than 6 (4-methoxybenzoyl), and derivative 7 with 3,4,5-trimethoxy substitution on the benzoyl ester was more potent than 5 with the 3-methoxy group. Also, derivative 10 with a 4-nitro moiety was more potent than 9 with the 3-nitro group. Further, the fluorinated derivatives 16 (4-fluoro-3-methyl), 17 (3-chloro-4-fluoro), 18 (2,4,5-trifluoro-3-methoxy), and 19 (2,3,4,5,6-pentafluoro) were more potent than 15 with only a single 4-fluoro substituent. Similarly, derivatives 13 (4-trifluoromethylbenzoate) and 26 (3-trifluoromethylcinnamate) showed increased antiproliferative activity against the three to five cancer cell lines compared with 4-fluorinated derivative 15. The fluorinated derivatives (13, 16–19, and 26: average IC₅₀ 4.9) were more potent than derivatives with small alkoxy groups (4–8: average IC₅₀ 7.1) and nitro groups (9, 10, and 24: average IC₅₀ 9.9) on the benzoate esters. Moreover, the 3-, 4-, or 3,5-chlorinated derivatives 21–24 as well as 25, which has 4-dichloromethyl substitution on the benzoate ester, were more potent than 20 with only a single 2-chloro substituent. Derivatives 21 (3-chlorobenzoate) and 23 (3,5-dichlorobenzoate) were equipotent and more potent than 22 (4-chlorobenzoate) and 24 (4-chloro-3-nitrobenzoate), which were also equipotent.

Additionally, among 17 derivatives (5–8, 10, 13, and 16–26), 13 derivatives (5, 7, 8, 13, 16–19, and 21–25) exhibited significant potency against MDA-MB-231 cell lines with IC₅₀ values ranging from 2.8 to 5.0 μM. Particularly, derivative 22 (4-chlorobenzoate, IC₅₀ 2.8 μM) exhibited the highest potency against this cell line. Meanwhile, the IC₅₀ values for the same 13 derivatives (5, 7, 8, 13, 16–19, and 21–25) ranged from 4.2 to 5.3 μM against the MCF-7 cell line. A similar range of potency (IC₅₀ 4.4–5.5 μM) was found with 15 derivatives (5, 7, 8, 13, and 16–26) against the A549 cell line. Furthermore, derivatives 5–8, 10, 13, and 15–26 were potent against the KB cell line with IC₅₀ values ranging from 4.1 to 5.3 μM. Moreover, derivatives 5–8, 10, 13, and 16–26 exhibited significant potency against the KB-VIN cell line with IC₅₀ values ranging from 3.1 to 5.7 μM. Particularly, derivative 26 (3-trifluoromethylcinnamate, IC₅₀ 3.1 μM) exhibited the highest potency against the KB-VIN cell line. Many derivatives displayed comparable potency against the KB and KB-VIN cell lines, in contrast to paclitaxel.

The 11-monoacylated derivatives with moderate potency against the three to five tested cancer cell lines contained 4-ethoxy- (8a) and 4-trifluoromethoxy- (14a) benzoyl esters. Furthermore, with some exceptions against certain cell lines, derivatives with unsubstituted (3a), methoxy (6a), trimethoxy (7a), nitro (9a, 10a), trifluoromethyl (11a-13a), fluoro (15a), 4-fluoro-3-methyl (16a), 2,4,5-trifluoro-3-methoxy (18a), and 3,5-dichloro (23a) substituted benzoate esters or nicotinoyl (27a) ester were less active or inactive. In contrast, the 15-monoacylated derivatives 3b, 7b, 9b, 10b, and 15b were inactive against all three to five tested cancer cell lines.

Intriguingly, the potent derivatives were generally effective against the P-gp-overexpressing MDR subline KB-VIN, while alkaloids such as paclitaxel and vincristine are less effective due to excretion from the MDR cells by P-gp. These results indicate that these derivatives are not substrates for P-gp.

To address the mechanism of action (MOA) of the kobusine (1) derivatives, we further examined the effects of derivatives on cell cycle progression. The TNBC cell line MDA-MB-231 was treated for 12 or 24 h with derivatives at threefold (3 × IC₅₀) concentrations of their IC₅₀. DMSO (CTRL) or 0.2 μM (3 × IC₅₀) combretastatin A-4 (CA-4) was used as a vehicle control or a tubulin polymerization inhibitor arresting cells at G2/M, respectively. Cell cycle distributions of treated cells were analyzed by flow cytometry (LSRII) after staining with propidium iodide (PI) in the presence of RNase. Time-course studies were carried out at 12 and 24 h using derivatives at 3 × IC₅₀ (Figure 3). With all derivatives tested, sub-G1 cells heavily accumulated after 12 h treatment at 3 × IC₅₀, while normal cell cycle progression was disrupted after 12 h treatment with 13 and 25 with decreasing numbers of cells in S and G2/M phases, resulting in accumulation of sub-G1. These results proved that derivatives 13 and 25 act through a similar MOA to induce sub-G1 accumulation within 12 h. In general, sub-G1 cells undergo apoptosis, unlike cytolysis. These observations suggested that derivatives 13 and 25 likely induced apoptosis within 12 h, but a detailed MOA analysis should be required to determine whether sub-G1 accumulation is due to apoptosis induction.

Figure 3.

Effects of derivatives 13 and 25 on the cell cycle. MDA-MB-231 (TNBC) cells were treated for 12 or 24 h with derivatives at a 3-fold (3 × IC₅₀) concentration of their IC₅₀. DMSO (CTRL) or 0.2 μM (3 × IC₅₀) combretastatin A-4 (CA-4) was used as a vehicle control or a tubulin polymerization inhibitor arresting cells in G2/M, respectively. Cell cycle distributions of treated cells were assessed by flow cytometry (LSRII) after staining with PI in the presence of RNase.

Conclusions

C-11 and -15 acylations of kobusine (1), a hetisine-type C₂₀-diterpenoid alkaloid, were carried out to provide 43 novel derivatives (2–10, 2b, 3a, 3b, 6a–16a, 7b, 9b, 10b, 13, 15–26, 15b, 18a, 23a, 27a). The natural alkaloid 1 and all synthesized derivatives (2–10, 2b, 3a, 3b, 6a–16a, 7b, 9b, 10b, 13, 15–26, 15b, 18a, 23a, 27a) were evaluated for antiproliferative activity against A549, MDA-MB-231, MCF-7, KB, and KB-VIN cancer cell lines. Several newly synthesized kobusine derivatives (particularly, 3, 5–8, 10, 13, 15–26) showed significant suppressive effects against these cell lines. In contrast, kobusine (1), 11,15-O-diacetylkobusine (2), 11-acylkobusine derivatives (3a, 6a, 9a, 11a, 12a, 15a, 27a) and 15-acylkobusine derivatives (2b, 3b, 7b, 9b, 10b, 15b) showed no effect. Among the active acyl derivatives, most 11,15-diacylkobusine derivatives (3, 6–10, 13, 15, 16, 18, 23) showed more potency compared with 11- and 15-acylkobusine derivatives (3a, 3b, 6a–10a, 7b, 9b, 10b, 13a, 15a, 15b, 16a, 18a, 23a). Derivatives 13 and 25 induced accumulation of sub-G1 cells within 12 h. 11,15-Diacylation of 1 as a lead appears to be critical for producing antiproliferative activity in this hetisine-type C₂₀-diterpenoid alkaloid class. Continual studies are merited to demonstrate the molecular MOA of sub-G1 accumulation by treatment with derivatives.

Experimental Section

Chemistry

IR spectra were recorded using a SHIMADZU model IRAffinity-1S (Shimadzu, Kyoto, Japan). NMR spectra were recorded in CDCl₃ on a JEOL model ECZ400 spectrometer (JEOL, Tokyo, Japan) with TMS as an internal standard. Mass spectrometry and high-resolution mass spectrometry were performed on a JEOL model JMS-700 mass spectrometer (JEOL, Tokyo, Japan).

Alkaloids

Kobusine (1) was extracted from A. yesoense var. macroyesoense, followed by purification and identification by methods described previously.^21,22 A total of 18 acyl derivatives, 11,15-O-diacetylkobusine (2),²³ 15-O-acetylkobusine (2b),²³ 11,15-dibenzoylkobusine (3),²³ 11-benzoylkobusine (3a),²³ 15-benzoylkobusine (3b),²³ 11,15-dianisoylkobusine (6),²⁴ 11-anisoylkobusine (6a),²⁴ 11,15-di-p-nitrobenzoylkobusine (10),¹⁷ 11-p-nitrobenzoylkobusine (10a),¹⁷ 15-p-nitrobenzoylkobusine (10b),¹⁷ 11-(2-trifluoromethylbenzoyl)kobusine (11a),¹⁹ 11-(3-trifluoromethylbenzoyl)kobusine (12a),¹⁴ 11-(4-trifluoromethoxybenzoyl)kobusine (14a),¹⁹ 11,15-di-(4-fluorobenzoyl)kobusine (15),¹⁹ 11-(4-fluorobenzoyl)kobusine (15a),¹⁹ 15-(4-fluorobenzoyl)kobusine (15b),¹⁹ 11,15-di-(3-trifluoromethylcinnamoyl)kobusine (26),¹⁹ and 11-(nicotinoyl)kobusine (27a),²⁴ were prepared by methods described previously.

General Procedure for the Synthesis of Kobusine Analogues

Kobusine (1) and an acyl chloride dissolved in pyridine were stirred at 60 °C (derivatives 13 and 18) or room temperature under Ar. The reaction solution was quenched with water, and ammonia water was added to pH 10. The reaction solution was extracted with CHCl₃ (three times). The combined organic layers were washed with saturated aq. NaHCO₃ and brine and dried over anhydrous MgSO₄. Then, the solvent was removed in vacuo. The crude products were purified by silica gel column chromatography eluting with n-hexane–CHCl₃ saturated with 28% aq. NH₃.

11,15-Di-(2-methoxybenzoyl)kobusine (4)

39% yield; colorless amorphous solid; HR–FABMS m/z: 582.2849 [M + H]⁺ calcd for C₃₆H₄₀NO₆, 582.2856; IR (ATR) ν_max cm^–1: 2928, 2859, 1721, 1601, 1581, 1234, 1130, 1022, 953; ¹H NMR (CDCl₃): δ 0.99 (3H, s, 18-CH₃), 3.78 and 3.84 (each 3H, s, OCH₃), 5.10 and 5.35 (each 1H, s, C=CH₂), 5.39 (1H, d, J = 4.5 Hz, 11-H), 5.77 (1H, s, 15-H), 6.36 and 6.71 (each 1H, t, J = 8.2 Hz, Ar–H), 6.87 (2H, d, J = 8.2 Hz, Ar–H), 7.32 and 7.40 (each 1H, t, J = 8.2 Hz, Ar–H), 7.73 and 7.77 (each 1H, d, J = 8.2 Hz, Ar–H); FABMS m/z: 582 [M + H]⁺.

11,15-Di-(3-methoxybenzoyl)kobusine (5)

76% yield; colorless amorphous solid; HR–FABMS m/z: 582.2867 [M + H]⁺ calcd for C₃₆H₄₀NO₆, 582.2856; IR (ATR) ν_max cm^–1: 2924, 2855, 1740, 1721, 1585, 1219, 1103, 1038, 957; ¹H NMR (CDCl₃): δ 0.95 (3H, s, 18-CH₃), 3.59 and 3.65 (each 3H, s, OCH₃), 5.15 and 5.36 (each 1H, s, C=CH₂), 5.46 (1H, d, J = 4.5 Hz, 11-H), 5.79 (1H, s, 15-H), 7.00 and 7.01 (each 1H, t, J = 8.2 Hz, Ar–H), 7.08 and 7.10 (each 1H, dd, J = 8.2, 2.7 Hz, Ar–H), 7.48 and 7.50 (each 1H, s, Ar–H), 7.51 and 7.57 (each 1H, d, J = 8.2 Hz, Ar–H); FABMS m/z: 582 [M + H]⁺.

11,15-Di-(3,4,5-trimethoxybenzoyl)kobusine (7)

15% yield; colorless amorphous solid; HR–FABMS m/z: 702.3277 [M + H]⁺ calcd for C₄₀H₄₈NO₁₀, 702.3278; IR (ATR) ν_max cm^–1: 2940, 2851, 1740, 1589, 1219, 1126, 995; ¹H NMR (CDCl₃): δ 0.96 (3H, s, 18-CH₃), 3.51 and 3.56 (each 6H, s, Ar-OCH₃), 3.81 and 3.82 (each 3H, s, Ar-OCH₃), 5.21 and 5.42 (each 1H, s, C=CH₂), 5.47 (1H, d, J = 5.0 Hz, 11-H), 5.81 (1H, s, 15-H), 7.16 and 7.26 (each 2H, s, Ar–H); FABMS m/z: 702 [M + H]⁺.

11-(3,4,5-Trimethoxybenzoyl)kobusine (7a)

35% yield; colorless amorphous solid; HR–FABMS m/z: 508.2692 [M + H]⁺ calcd for C₃₀H₃₈NO₆, 508.2699; IR (ATR) ν_max cm^–1: 3449, 2940, 2866, 1713, 1589, 1219, 1123, 1034, 1003, 961; ¹H NMR (CDCl₃): δ 0.98 (3H, s, 18-CH₃), 3.87 (6H, s, Ar-OCH₃), 3.90 (3H, s, Ar-OCH₃), 4.01 (1H, d, J = 8.2 Hz, 15-H), 5.12 and 5.29 (each 1H, s, C=CH₂), 5.38 (1H, d, J = 5.0 Hz, 11-H), 7.24 (2H, s, Ar–H); FABMS m/z: 508 [M + H]⁺.

15-(3,4,5-Trimethoxybenzoyl)kobusine (7b)

12% yield; colorless amorphous solid; HR–FABMS m/z: 508.2726 [M + H]⁺ calcd for C₃₀H₃₈NO₆, 508.2699; IR (ATR) ν_max cm^–1: 3449, 2924, 2851, 1736, 1589, 1227, 1130, 1038, 988; ¹H NMR (CDCl₃): δ 0.97 (3H, s, 18-CH₃), 3.91 (6H, s, Ar-OCH₃), 3.92 (3H, s, Ar-OCH₃), 4.09 (1H, bs, 11-H), 5.24 and 5.38 (each 1H, s, C=CH₂), 5.71 (1H, s, 15-H), 7.30 (2H, s, Ar–H); FABMS m/z: 508 [M + H]⁺.

11,15-Di-(4-ethoxybenzoyl)kobusine (8)

15% yield; colorless amorphous solid; HR–FABMS m/z: 610.3156 [M + H]⁺ calcd for C₃₈H₄₄NO₆, 610.3169; IR (ATR) ν_max cm^–1: 2928, 2866, 1736, 1605, 1250, 1169, 1042, 957; ¹H NMR (CDCl₃): δ 0.98 (3H, s, 18-CH₃), 1.38 and 1.41 (each 3H, t, J = 7.2 Hz, OCH₂CH₃), 3.98 (4H, q, J = 7.2 Hz, OCH₂CH₃), 5.12 and 5.35 (each 1H, s, C=CH₂), 5.40 (1H, d, J = 5.0 Hz, 11-H), 5.74 (1H, s, 15-H), 6.65 (4H, d, J = 8.6 Hz, Ar–H), 7.84 and 7.88 (each 2H, d, J = 8.6 Hz, Ar–H); FABMS m/z: 610 [M + H]⁺.

11-(4-Ethoxybenzoyl)kobusine (8a)

30% yield; colorless amorphous solid; HR–FABMS m/z: 462.2656 [M + H]⁺ calcd for C₂₉H₃₆NO₄, 462.2644; IR (ATR) ν_max cm^–1: 3456, 2943, 2866, 1740, 1605, 1213, 1111, 1038; ¹H NMR (CDCl₃): δ 0.99 (3H, s, 18-CH₃), 1.44 (3H, t, J = 7.2 Hz, OCH₂CH₃), 4.00 (1H, s, 15-H), 4.08 (2H, q, J = 7.2 Hz, OCH₂CH₃), 5.09 and 5.27 (each 1H, s, C=CH₂), 5.36 (1H, d, J = 5.0 Hz, 11-H), 6.89 and 7.89 (each 2H, d, J = 8.6 Hz, Ar–H); FABMS m/z: 462 [M + H]⁺.

11,15-Di-(3-nitrobenzoyl)kobusine (9)

47% yield; colorless amorphous solid; HR–FABMS m/z: 612.2354 [M + H]⁺ calcd for C₃₄H₃₄N₃O₈, 612.2346; IR (ATR) ν_max cm^–1: 2924, 2851, 1717, 1616, 1531, 1354, 1258, 1134, 1072, 957; ¹H NMR (CDCl₃): δ 0.98 (3H, s, 18-CH₃), 5.20 and 5.43 (each 1H, s, C=CH₂), 5.55 (1H, d, J = 4.5 Hz, 11-H), 5.86 (1H, s, 15-H), 7.44 and 7.50 (each 1H, t, J = 8.2 Hz, Ar–H), 8.28 (4H, m, Ar–H), 8.63 and 8.70 (each 1H, t, J = 1.8 Hz, Ar–H); FABMS m/z: 612 [M + H]⁺.

11-(3-Nitrobenzoyl)kobusine (9a)

11% yield; colorless amorphous solid; HR–FABMS m/z: 463.2261 [M + H]⁺ calcd for C₂₇H₃₁N₂O₅, 463.2233; IR (ATR) ν_max cm^–1: 3429, 2924, 2855, 1724, 1616, 1528, 1346, 1250, 1134, 1072, 957; ¹H NMR (CDCl₃): δ 0.99 (3H, s, 18-CH₃), 4.06 (1H, s, 15-H), 5.10 and 5.27 (each 1H, s, C=CH₂), 5.42 (1H, d, J = 4.1 Hz, 11-H), 7.64 (1H, t, J = 8.2 Hz, Ar–H), 8.27 and 8.41 (each 1H, d, J = 8.2 Hz, Ar–H), 8.82 (1H, s, Ar–H); FABMS m/z: 463 [M + H]⁺.

15-(3-Nitrobenzoyl)kobusine (9b)

7% yield; colorless amorphous solid; HR–FABMS m/z: 463.2261 [M + H]⁺ calcd for C₂₇H₃₁N₂O₅, 463.2233; IR (ATR) ν_max cm^–1: 3456, 2924, 2855, 1724, 1616, 1531, 1350, 1258, 1134, 1072, 961; ¹H NMR (CDCl₃): δ 0.96 (3H, s, 18-CH₃), 4.14 (1H, bs, 11-H), 5.26 and 5.40 (each 1H, s, C=CH₂), 5.76 (1H, s, 15-H), 7.67 (1H, t, J = 8.2 Hz, Ar–H), 8.34 and 8.44 (each 1H, d, J = 8.2 Hz, Ar–H), 8.87 (1H, s, Ar–H); FABMS m/z: 463 [M + H]⁺.

11,15-Di-(4-trifluoromethylbenzoyl)kobusine (13)

86% yield; colorless amorphous solid; HR–FABMS m/z: 658.2381 [M + H]⁺ calcd for C₃₆H₃₄F₆NO₄, 658.2392; IR (ATR) ν_max cm^–1: 2932, 2870, 1717, 1585, 1258, 1119, 1065, 953; ¹H NMR (CDCl₃): δ 0.97 (3H, s, 18-CH₃), 5.17 and 5.39 (each 1H, s, C=CH₂), 5.49 (1H, d, J = 4.5 Hz, 11-H), 5.80 (1H, s, 15-H), 7.42, 7.44, 7.98 and 8.02 (each 2H, d, J = 8.6 Hz, Ar–H); FABMS m/z: 658 [M + H]⁺.

11-(4-Trifluoromethylbenzoyl)kobusine (13a)

8% yield; colorless amorphous solid; HR–FABMS m/z: 486.2256 [M + H]⁺ calcd for C₂₈H₃₁F₃NO₃, 486.2256; IR (ATR) ν_max cm^–1: 3333, 2920, 2851,1717, 1601, 1582, 1277, 1123, 1065; ¹H NMR (CDCl₃): δ 1.08 (3H, s, 18-CH₃), 4.10 (1H, s, 15-H), 5.13 and 5.28 (each 1H, s, C=CH₂), 5.35 (1H, d, J = 4.5 Hz, 11-H), 7.69 and 8.05 (each 2H, d, J = 8.1 Hz, Ar–H); FABMS m/z: 486 [M + H]⁺.

11,15-Di-(4-fluoro-3-methylbenzoyl)kobusine (16)

45% yield; colorless amorphous solid; HR–FABMS m/z: 586.2764 [M + H]⁺ calcd for C₃₆H₃₈F₂NO₄, 586.2769; IR (ATR) ν_max cm^–1: 2928, 2866, 1709, 1593, 1231, 1115, 1022, 957; ¹H NMR (CDCl₃): δ 0.96 (3H, s, 18-CH₃), 2.00 and 2.02 (each 3H, d, J = 1.8 Hz, Ar-CH₃), 5.14 and 5.37 (each 1H, s, C=CH₂), 5.46 (1H, d, J = 4.5 Hz, 11-H), 5.77 (1H, s, 15-H), 6.83 and 6.86 (each 1H, t, J = 8.6 Hz, Ar–H), 7.42 (1H, dd, J = 7.3, 1.3 Hz, Ar–H), 7.80 (3H, m, Ar–H); FABMS m/z: 586 [M + H]⁺.

11-(4-Fluoro-3-methylbenzoyl)kobusine (16a)

25% yield; colorless amorphous solid; HR–FABMS m/z: 450.2439 [M + H]⁺ calcd for C₂₈H₃₃FNO₃, 450.2444; IR (ATR) ν_max cm^–1: 3456, 2928, 2870, 1709, 1593, 1231, 1115, 1034, 957; ¹H NMR (CDCl₃): δ 0.97 (3H, s, 18-CH₃), 2.29 (3H, d, J = 1.8 Hz, Ar-CH₃), 3.99 (1H, d, J = 7.7 Hz, 15-H), 5.07 and 5.25 (each 1H, s, C=CH₂), 5.35 (1H, d, J = 4.6 Hz, 11-H), 7.02 (1H, t, J = 8.6 Hz, Ar–H), 7.75 (1H, m, Ar–H), 7.81 (1H, dd, J = 7.2, 1.3 Hz, Ar–H). FABMS m/z: 450 [M + H]⁺.

11,15-Di-(3-chloro-4-fluorobenzoyl)kobusine (17)

58% yield; colorless amorphous solid; HR–FABMS m/z: 626.1689 [M + H]⁺ calcd for C₃₄H₃₂Cl₂F₂NO₄, 626.1676; IR (ATR) ν_max cm^–1: 2932, 2866, 1717, 1597, 1227, 1103, 1061, 957; ¹H NMR (CDCl₃): δ 0.96 (3H, s, 18-CH₃), 5.15 and 5.36 (each 1H, s, C=CH₂), 5.46 (1H, d, J = 5.0 Hz, 11-H), 5.77 (1H, s, 15-H), 7.01 and 7.06 (each 1H, t, J = 8.6 Hz, Ar–H), 7.85 (2H, m, Ar–H), 7.90 and 7.96 (each 1H, dd, J = 7.2, 2.3 Hz, Ar–H); FABMS m/z: 630 [M + 4 + H]⁺, 628 [M + 2 + H]⁺, 626 [M + H]⁺.

11,15-Di-(2,4,5-trifluoro-3-methoxybenzoyl)kobusine (18)

55% yield; colorless oil; HR–FABMS m/z: 690.2303 [M + H]⁺ calcd for C₃₆H₃₄F₆NO₆, 690.2290; IR (ATR) ν_max cm^–1: 2943, 2870, 1717, 1620, 1234, 1103, 1057, 957; ¹H NMR (CDCl₃): δ 0.97 (3H, s, 18-CH₃), 3.94 and 3.95 (each 3H, s, Ar-OCH₃), 5.14 and 5.38 (each 1H, s, C=CH₂), 5.40 (1H, d, J = 5.0 Hz, 11-H), 5.73 (1H, s, 15-H), 7.29 and 7.42 (each 1H, ddd, J = 10.4, 8.6, 6.4 Hz, Ar–H); FABMS m/z: 690 [M + H]⁺.

11- (2,4,5-Trifluoro-3-methoxybenzoyl)kobusine (18a)

19% yield; colorless amorphous solid; HR–FABMS m/z: 502.2200 [M + H]⁺ calcd for C₂₈H₃₁F₃NO₄, 502.2205; IR (ATR) ν_max cm^–1: 3391, 2932, 2859, 1724, 1223, 1103, 1057, 945; ¹H NMR (CDCl₃): δ 0.99 (3H, s, 18-CH₃), 3.98 (1H, s, 15-H), 4.04 (3H, s, Ar-OCH₃), 5.05 and 5.26 (each 1H, s, C=CH₂), 5.41 (1H, d, J = 4.9 Hz, 11-H), 7.48 (1H, ddd, J = 10.4, 8.6, 6.4 Hz, Ar–H); FABMS m/z: 502 [M + H]⁺.

11,15-Di-(2,3,4,5,6-pentafluorobenzoyl)kobusine (19)

26% yield; dark-brown oil; HR–EIMS m/z: 701.1597 [M]⁺ calcd for C₃₄H₂₅F₁₀NO₄, 701.1624; IR (ATR) ν_max cm^–1: 2931, 2870, 1728, 1651, 1523, 1497, 1330, 1227, 995; ¹H NMR (CDCl₃): δ 1.00 (3H, s, 18-CH₃), 5.16 and 5.35 (each 1H, s, C=CH₂), 5.43 (1H, d, J = 4.5 Hz, 11-H), 5.75 (1H, s, 15-H); EIMS m/z: 701 [M]⁺, 506 [M – COC₆F₅]⁺, 195 [COC₆F₅]⁺.

11,15-Di-(2-chlorobenzoyl)kobusine (20)

59% yield; colorless amorphous solid; HR–EIMS m/z: 589.1797 [M]⁺ calcd for C₃₄H₃₃Cl₂NO₄, 589.1787; IR (ATR) ν_max cm^–1: 2931, 2870, 2843, 1721, 1589, 1246, 1119, 1045; ¹H NMR (CDCl₃): δ 0.97 (3H, s, 18-CH₃), 5.13 and 5.36 (each 1H, s, C=CH₂), 5.42 (1H, d, J = 4.5 Hz, 11-H), 5.81(1H, s, 15-H), 6.74, 7.06, 7.27, and 7.36 (each 1H, t, J = 7.7 Hz, Ar–H), 7.37, 7.40, 7.67, and 7.69 (each 1H, d, J = 7.7 Hz, Ar–H); EIMS m/z: 593 [M + 4]⁺, 591 [M + 2]⁺, 589 [M]⁺, 450 [M – COC₆H₄Cl]⁺, 141 [COC₆H₄Cl + 2]⁺, 139 [COC₆H₄Cl]⁺.

11,15-Di-(3-chlorobenzoyl)kobusine (21)

69% yield; colorless oil; HR–EIMS m/z: 589.1767 [M]⁺ calcd for C₃₄H₃₃Cl₂NO₄, 589.1787; IR (ATR) ν_max cm^–1: 2931, 2866, 2847, 1713, 1574, 1250, 1126, 1072; ¹H NMR (CDCl₃): δ 0.96 (3H, s, 18-CH₃), 5.14 and 5.36 (each 1H, s, C=CH₂), 5.47 (1H, d, J = 4.9 Hz, 11-H), 5.79 (1H, s, 15-H), 7.15 and 7.20 (each 1H, t, J = 8.2 Hz, Ar–H), 7.42 and 7.46 (each 1H, d, J = 8.2 Hz, Ar–H), 7.81 (2H, d, J = 8.2 Hz, Ar–H), 7.88 and 7.90 (each 1H, s, Ar–H); EIMS m/z: 593 [M + 4]⁺, 591 [M + 2]⁺, 589 [M]⁺, 450 [M – COC₆H₄Cl]⁺, 141 [COC₆H₄Cl + 2]⁺, 139 [COC₆H₄Cl]⁺.

11,15-Di-(4-chlorobenzoyl)kobusine (22)

28% yield; colorless amorphous solid; HR–EIMS m/z: 589.1797 [M⁺] calcd for C₃₄H₃₃Cl₂NO₄, 589.1787; IR (ATR) ν_max cm^–1: 2936, 2866, 2847, 1713, 1593, 1261, 1119, 1092; ¹H NMR (CDCl₃): δ 0.97 (3H, s, 18-CH₃), 5.14 and 5.36 (each 1H, s, C=CH₂), 5.45 (1H, d, J = 4.9 Hz, 11-H), 5.76 (1H, s, 15-H), 7.18, 7.21, 7.84, and 7.86 (each 2H, dt, J = 8.6, 1.8 Hz, Ar–H); EIMS m/z: 593 [M + 4]⁺, 591 [M + 2]⁺, 589 [M]⁺, 450 [M – COC₆H₄Cl]⁺, 141 [COC₆H₄Cl + 2]⁺, 139 [COC₆H₄Cl]⁺.

11,15-Di-(3,5-dichlorobenzoyl)kobusine (23)

75% yield; colorless oil; HR–EIMS m/z: 657.0984 [M]⁺ calcd for C₃₄H₃₁Cl₄NO₄, 657.1007; IR (ATR) ν_max cm^–1: 2928, 2866, 1717, 1570, 1254, 1146, 1099; ¹H NMR (CDCl₃): δ 0.97 (3H, s, 18-CH₃), 5.17 and 5.40 (each 1H, s, C=CH₂), 5.47 (1H, d, J = 5.0 Hz, 11-H), 5.77 (1H, s, 15-H), 7.43 and 7.46 (each 1H, t, J = 1.8 Hz, Ar–H), 7.72 and 7.74 (each 2H, d, J = 1.8 Hz, Ar–H); EIMS m/z: 667 [M + 8]⁺, 665 [M + 6]⁺, 661 [M + 4]⁺, 659 [M + 2]⁺, 657 [M]⁺, 484 [M – COC₆H₃Cl₂]⁺, 175 [COC₆H₃Cl₂ + 2]⁺, 173 [COC₆H₃Cl₂]⁺.

11-(3,5-Dichlorobenzoyl)kobusine (23a)

10% yield; colorless amorphous solid; HR–EIMS m/z: 485.1518 [M]⁺ calcd for C₂₇H₂₉Cl₂NO₃, 485.1524; IR (ATR) ν_max cm^–1: 2970, 2936, 1738, 1570, 1215; ¹H NMR (CDCl₃): δ 0.99 (3H, s, 18-CH₃), 4.03 (1H, s, 15-H), 5.08 and 5.26 (each 1H, s, C=CH₂), 5.35 (1H, d, J = 4.5 Hz, 11-H), 7.53 (1H, t, J = 1.8 Hz, Ar–H), 7.81 (2H, d, J = 1.8 Hz, Ar–H); EIMS m/z: 489 [M + 4]⁺, 487 [M + 2]⁺, 485 [M]⁺, 312 [M – COC₆H₃Cl₂]⁺, 173 [COC₆H₃Cl₂]⁺.

11,15-Di-(4-chloro-3-nitrobenzoyl)kobusine (24)

11% yield; colorless amorphous solid; HR–FABMS m/z: 680.1559 [M + H]⁺ calcd for C₃₄H₃₂Cl₂N₃O₈, 680.1566; IR (ATR) ν_max cm^–1: 2924, 2856, 1717, 1605, 1535, 1242, 1103, 1049, 957; ¹H NMR (CDCl₃): δ 0.98 (3H, s, 18-CH₃), 5.17 and 5.38 (each 1H, s, C=CH₂), 5.50 (1H, d, J = 4.5 Hz, 11-H), 5.81 (1H, s, 15-H), 7.51 and 7.56 (each 1H, d, J = 8.2 Hz, Ar–H), 8.06 and 8.08 (each 1H, dd, J = 8.2, 1.8 Hz, Ar–H), 8.22 and 8.29 (each 1H, d, J = 1.8 Hz, Ar–H); FABMS m/z: 684 [M + 4 + H]⁺, 682 [M + 2 + H]⁺, 680 [M + H]⁺.

11,15-Di-(4-dichloromethylbenzoyl)kobusine (25)

62% yield; colorless amorphous solid; HR–FABMS m/z: 686.1404 [M + H]⁺ calcd for C₃₆H₃₆Cl₄NO₄, 686.1398; IR (ATR) ν_max cm^–1: 2924, 2855, 1713, 1612, 1582, 1231, 1107, 1018, 953; ¹H NMR (CDCl₃): δ 0.96 (3H, s, 18-CH₃), 5.14 and 5.34 (each 1H, s, C=CH₂), 5.47 (1H, d, J = 4.5 Hz, 11-H), 5.79 (1H, s, 15-H), 6.63 and 6.65 (each 1H, s, Ar-CHCl₂), 7.41, 7.42, 7.95, and 7.99 (each 1H, d, J = 8.6 Hz, Ar–H); FABMS m/z: 694 [M + 8 + H]⁺, 692 [M + 6 + H]⁺, 690 [M + 4 + H]⁺, 688 [M + 2 + H]⁺, 686 [M + H]⁺.

Cell Culture, Cytotoxicity, and Cell Cycle Analysis

All cell lines used in this study were obtained from American Type Culture Collection (ATCC, Virginia, USA) or UNC Lineberger Comprehensive Cancer Center (North Carolina, USA), except KB-VIN (MDR subline established from KB), which was provided by Professor Y.-C. Cheng (Yale University, Connecticut, USA). All cell lines were cultured in RPMI 1640 medium containing 25 mM HEPES and 2 mM l-glutamine (Corning, New York, USA), supplemented with 10% fetal bovine serum (Sigma-Aldrich, Missouri, USA), 100 μg/mL streptomycin, 100 IU penicillin, and 0.25 μg/mL amphotericin B (Corning, New York, USA). KB-VIN were maintained in a medium containing 100 nM vincristine (Sigma-Aldrich, Missouri, USA). Cells were cultured at 37 °C in a humidified 5% CO₂ atmosphere.

Antiproliferative activity was assessed by the sulforhodamine B (SRB) method as described before.²⁵ Briefly, all derivatives were prepared at 10 mM with DMSO, and the highest DMSO concentration in the cultures (0.4% v/v) used for the antiproliferative activity assay had no effect on cell growth. Freshly trypsinized cell suspensions were seeded in 96-well microtiter plates at densities of 4000–11,000 cells per well with derivatives for 72 h, followed by fixation in 10% trichloroacetic acid and then staining with 0.04% SRB. The protein-bound dye was solubilized by 10 mM Tris base, and the absorbance was measured at 515 nm using a ELx800 microplate reader operated by Gen5 software (BioTek, Vermont, USA). The IC₅₀ value was calculated from at least three independent experiments performed in duplicate.

MDA-MB-231 (1 × 10⁵ cells/well) cells were seeded in a 12-well plate 24 h prior to treatment with derivatives. After 12 or 24 h treatment with derivatives at a concentration 3-fold of their IC₅₀ value (3 × IC₅₀), cells were harvested and fixed with 70% EtOH, followed by staining with PI containing RNase (BD Bioscience). Stained cells were analyzed using a flow cytometer (BD LSRII, BD Biosciences). 200 nM CA-4 was used as tubulin polymerization inhibitor arresting cells in G2/M.

Supporting Information Available

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsomega.2c02363.

• ¹H NMR spectra for derivatives 4, 5, 7–9, 7a–9a, 7b, 9b, 13, 13a, 16–25, 16a, 18a, and 23a (PDF)

Author Contributions

^§ K.W. and M.G. contributed equally to this work.

The authors declare no competing financial interest.